MIRA Says Oral Ketamine Analog, Ketamir-2, Showed Significantly Greater Efficacy Than FDA-Approved Treatments Gabapentin (Neurontin) And Pregabalin (Lyrica) In Recent Preclinical Models Of Neuropathic Pain - Filing

Benzinga · Oct 21, 2024 19:10

The Company is actively conducting additional studies focused on chemotherapy-induced and diabetic neuropathy. These studies are part of the broader development program, which also includes plans to initiate PTSD trials. Notably, MIRA Pharmaceuticals is exploring government funding opportunities to support the PTSD program.

The Company remains on track to submit an Investigational New Drug (IND) application by the end of 2024, with Phase I clinical trials expected to begin in Q1 2025. Phase II trials are projected to start by late 2025.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

MIRA Says Oral Ketamine Analog, Ketamir-2, Showed Significantly Greater Efficacy Than FDA-Approved Treatments Gabapentin (Neurontin) And Pregabalin (Lyrica) In Recent Preclinical Models Of Neuropathic Pain - Filing

Risk Disclaimer